Special Issue "Personalized Medicine for Schizophrenia Spectrum Disorders"

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: 15 February 2024 | Viewed by 1186

Special Issue Editor

Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, 00179 Rome, Italy
Interests: schizophrenia; psychosis; first episode psychoses; symptoms’ exacerbation; acute phase; biomarkers; brain; cognitive deficits; insight; personalised treatment; treatment resistant

Special Issue Information

Dear Colleagues,

Schizophrenia remains one of the most debilitating diseases, affecting 20 million people worldwide. It has been estimated that the economic burden associated with schizophrenia ranges from USD 94 million to USD 104 billion annually, placing it among the leading causes of global ill-health and disability.

Schizophrenia is a complex multifactorial brain disorder that commonly emerges in late adolescence or early adulthood, with a peak between ages 18 and 25. In its most common form, schizophrenia is characterized by a loss of contact with reality, including delusions, hallucinations, unusual or bizarre behavior, and impaired cognition and social interactions.

Despite more than 30 years of neuroscientific, pharmacological, and psychosocial research, we still do not have a comprehensive understanding of the pathophysiology of this disorder; therefore, the overall prognosis of schizophrenia has improved only marginally.  It is well known that the chronicity of the disease has a great impact on the functional outcome and that a frank psychotic episode is usually preceded by a prodromal phase of attenuated psychotic symptoms and decline in functioning. In the prodromal phase, patients experience changes in feelings, thoughts, perceptions, and behavior. Intervention during this phase could prevent the transition to psychosis and is therefore of high relevance.

In a joint effort, the Special Issue of the Journal of Personalized Medicine aims to provide insights into reliable biomarkers that can be used as diagnostics or predictors of treatment outcomes and to promote tailored therapeutic interventions. Contributions will include, but are not limited to, original research articles and literature reviews dealing with biomarker identification through clinical, neuroimaging, and genetic approaches, targeted assessment tools, and pharmacotherapy, along with non-pharmacological interventions. Last but not least, research shedding light on the use and implementation of machine learning algorithms and their application in clinical practice to improve precision in mental health interventions are welcome.

Dr. Nerisa Banaj
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • biomarkers
  • targeted assessment
  • neuropsychology
  • cognitive enhancers
  • clinical awareness
  • metacognition
  • early diagnosis
  • relapse prevention
  • best clinical practice

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Brain Network Topology in Deficit and Non-Deficit Schizophrenia: Application of Graph Theory to Local and Global Indices
J. Pers. Med. 2023, 13(5), 799; https://doi.org/10.3390/jpm13050799 - 06 May 2023
Viewed by 822
Patients with deficit schizophrenia (SZD) suffer from primary and enduring negative symptoms. Limited pieces of evidence and neuroimaging studies indicate they differ from patients with non-deficit schizophrenia (SZND) in neurobiological aspects, but the results are far from conclusive. We applied for the first [...] Read more.
Patients with deficit schizophrenia (SZD) suffer from primary and enduring negative symptoms. Limited pieces of evidence and neuroimaging studies indicate they differ from patients with non-deficit schizophrenia (SZND) in neurobiological aspects, but the results are far from conclusive. We applied for the first time, graph theory analyses to discriminate local and global indices of brain network topology in SZD and SZND patients compared with healthy controls (HC). High-resolution T1-weighted images were acquired for 21 SZD patients, 21 SZND patients, and 21 HC to measure cortical thickness from 68 brain regions. Graph-based metrics (i.e., centrality, segregation, and integration) were computed and compared among groups, at both global and regional networks. When compared to HC, at the regional level, SZND were characterized by temporoparietal segregation and integration differences, while SZD showed widespread alterations in all network measures. SZD also showed less segregated network topology at the global level in comparison to HC. SZD and SZND differed in terms of centrality and integration measures in nodes belonging to the left temporoparietal cortex and to the limbic system. SZD is characterized by topological features in the network architecture of brain regions involved in negative symptomatology. Such results help to better define the neurobiology of SZD (SZD: Deficit Schizophrenia; SZND: Non-Deficit Schizophrenia; SZ: Schizophrenia; HC: healthy controls; CC: clustering coefficient; L: characteristic path length; E: efficiency; D: degree; CCnode: CC of a node; CCglob: the global CC of the network; Eloc: efficiency of the information transfer flow either within segregated subgraphs or neighborhoods nodes; Eglob: efficiency of the information transfer flow among the global network; FDA: Functional Data Analysis; and Dmin: estimated minimum densities). Full article
(This article belongs to the Special Issue Personalized Medicine for Schizophrenia Spectrum Disorders)
Show Figures

Figure 1

Back to TopTop